SCHEMBL20032382

SCHEMBL20032382

CCOc1ccc(-c2ccc(C(CC)CC)cc2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.42
FAAH O00519 1/20 0.42
NAAA Q02083 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
FFAR1 O14842 2/20 0.40
CYP17A1 P05093 2/20 0.40
PPARD Q03181 1/20 0.39
PTGS2 P35354 3/20 0.38
PTGS1 P23219 2/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18713324 0.88 FFAR1 (0.38) FAAHALDH1A1KDM4EMEN1POLB
SCHEMBL20032293 0.87 KDM1A (0.46) KDM1AFAAHL3MBTL1ALDH1A1MEN1
SCHEMBL20032324 0.86 CYP17A1 (0.52) NAAAALDH1A1MEN1MAPTKMT2A
SCHEMBL9484876 0.85 L3MBTL1 (0.53) KDM1AFAAHNAAAL3MBTL1ALDH1A1
SCHEMBL16574198 0.80 KDM1A (0.46) KDM1AFAAHNAAAL3MBTL1ALDH1A1
SCHEMBL10976808 0.79 CYP17A1 (0.48) KDM1AFAAHNAAAL3MBTL1ALDH1A1
SCHEMBL20032311 0.78 HTT (0.46) KDM1AL3MBTL1ALDH1A1KDM4EPOLB
SCHEMBL21164508 0.78 KDM1A (0.42) KDM1AFAAHL3MBTL1ALDH1A1MEN1
SCHEMBL10980023 0.78 CYP17A1 (0.42) KDM1AFAAHNAAAL3MBTL1ALDH1A1
SCHEMBL9476831 0.78 KDM1A (0.44) KDM1AFAAHNAAAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
US-10946018-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ROIVANT SCIENCES GMBH (CH) 2021-03-16 US disclosed
US-20200237760-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ROIVANT SCIENCES GMBH (CH) 2020-07-30 US disclosed
US-10660893-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ROIVANT SCIENCES, GmbH (CH) 2020-05-26 US disclosed
US-20190282575-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2019-09-19 US disclosed
US-20180092918-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10660893-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A KDM1A 1444/4885FAAH 160/4885NAAA 1965/4885
US-20200237760-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A KDM1A 1444/4885FAAH 160/4885NAAA 1965/4885
US-20180092918-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A KDM1A 1444/4885FAAH 160/4885NAAA 1965/4885
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A KDM1A 1444/4885FAAH 160/4885NAAA 1965/4885
US-20190282575-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A KDM1A 1444/4885FAAH 160/4885NAAA 1965/4885
US-10946018-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A KDM1A 1444/4885FAAH 160/4885NAAA 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.